Trial Profile
A Phase 1, Open-Label Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of [14C] Pacritinib Following a Single Oral Dose in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors CTI BioPharma
- 20 Apr 2016 Pharmacokinetic results (n=6) presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 20 Apr 2016 Results published in the CTI BioPharma media release.
- 14 Apr 2016 New trial record